Buttonwood Financial Advisors Inc. Sells 82,000 Shares of Kenvue Inc. (NYSE:KVUE)

Buttonwood Financial Advisors Inc. reduced its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 65.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,130 shares of the company’s stock after selling 82,000 shares during the quarter. Buttonwood Financial Advisors Inc.’s holdings in Kenvue were worth $921,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Novare Capital Management LLC raised its holdings in Kenvue by 6.2% during the fourth quarter. Novare Capital Management LLC now owns 491,970 shares of the company’s stock worth $10,504,000 after acquiring an additional 28,616 shares in the last quarter. Anderson Hoagland & Co. bought a new stake in Kenvue in the fourth quarter valued at approximately $1,656,000. Juncture Wealth Strategies LLC lifted its position in shares of Kenvue by 60.5% in the fourth quarter. Juncture Wealth Strategies LLC now owns 16,713 shares of the company’s stock valued at $357,000 after buying an additional 6,302 shares during the last quarter. GSB Wealth Management LLC boosted its stake in shares of Kenvue by 0.9% during the 4th quarter. GSB Wealth Management LLC now owns 149,322 shares of the company’s stock worth $3,188,000 after acquiring an additional 1,323 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Kenvue stock opened at $20.79 on Monday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $39.85 billion, a PE ratio of 37.79, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s 50-day moving average price is $22.14 and its two-hundred day moving average price is $21.80.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the previous year, the firm posted $0.31 EPS. The firm’s revenue was down .4% on a year-over-year basis. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Bank of America raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.